Graz

• A Randomized, Placebo-controlled, Double-blind, Parallel group, 6 Month Study to Evaluate the Safety, Tolerability, and Potential Efficacy o … Not authorised
  2022-500828-30-00 4 Early Alzheimer´s Disease
• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised
  2022-501463-40-00 5 Locally Advanced or Metastatic Cholangiocarcinoma
• Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised
  2022-501535-16-00 5 Atopic Dermatitis (AD)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Pending
  2022-501389-23-02 4 end-stage renal disease or otherwise an insufficient kidney function
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• Image-Verapamil SR in Adults with Type 1 Diabetes (Image-VER-A-T1D) Pending
  2024-518554-17-00 4 type 1 diabetes mellitus
• SGLT2 lnhibition in Hemodialysis (DAPA-HD) Pending
  2024-518591-31-00 4 Chronic Kidney Disease
• Psilocybin in treatment-resistant depression Pending
  2024-518654-16-01 4 Treatment-resistant depression
• Prevention of heart disease in heart-healthy patients with diabetes based on a special parameter (NT-proBNP) Pending
  2024-519051-28-01 6 Diabetes mellitus Type 2
• RESCAP to prevent peri- and post-surgical complications in open-heart surgery. Pending
  2025-520551-84-00 5 systemic inflammation as side-effect of heart-lung machine during card
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de no … Pending
  2025-520641-69-00 4 Kidney disease
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 5 Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• DIRECTION Study Pending
  2025-524495-39-00 6 Chronic Rhinosinusitis with Nasal Polyps
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis

Showing 1–24 of 390 trials